Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Lipitor OTC Bid Would Face FDA Evolving On Switch Innovation

This article was originally published in The Tan Sheet

Executive Summary

Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.

You may also be interested in...



In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers

Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.

In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers

Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.

Petitions Denied For ‘Pharmacist Category’ Nonprescription Viagra, Lipitor, Chantix

The petitioner offers no evidence to support establishing a “Pharmacists Category of Drugs Behind the Counter” status for nonprescription sales with continued Rx distribution of Viagra, Lipitor, Narcan and Chantix, CDER Director Woodcock says in rejecting a petition on each drug.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel